Roivant executives used the company’s fourth-quarter and fiscal-year earnings call to highlight new clinical data from its development portfolio, upcoming readouts and its strengthened balance sheet following a settlement with Moderna.
Matthew Klein, CEO of Roivant, said the company has had “a pretty wild 12 months,” citing progress across multiple programs and a series of expected milestones over the next year. The most prominent update was preliminary open-label data from a study of IMVT-1402 in difficult-to-treat rheumatoid arthritis, a program run by Immunovant (NASDAQ:IMVT).